NASDAQ:QURE

uniQure Stock Forecast, Price & News

Top-Rated Stocks

$38.85

-0.41 (-1.04 %)

(As of 01/25/2021 10:55 AM ET)

Add

Compare

Today's Range

$38.65

Now: $38.85▼

$39.46

50-Day Range

$36.13

MA: $41.49▼

$50.09

52-Week Range

$34.38

Now: $38.85▼

$71.45

Volume1,501 shs

Average Volume394,086 shs

Market Capitalization$1.73 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.19

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

MarketRank^™

Overall MarketRank^™

1.93 out of 5 stars

Medical Sector

75th out of 1,923 stocks

Pharmaceutical Preparations Industry

34th out of 773 stocks

4.5 Analyst's Opinion

Consensus Rating
uniQure has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.92, uniQure has a forecasted upside of 70.5% from its current price of $39.26.
Amount of Analyst Coverage
uniQure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
uniQure has received 598 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
uniQure has received 433 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
uniQure has received 58.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about uniQure and other stocks. Vote “Outperform” if you believe QURE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
uniQure does not currently pay a dividend.
Dividend Growth
uniQure does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,055,748.00 in company stock.
Percentage Held by Insiders
Only 2.79% of the stock of uniQure is held by insiders.
Percentage Held by Institutions
78.34% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for uniQure are expected to grow in the coming year, from ($1.59) to ($0.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of uniQure is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of uniQure is -10.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
uniQure has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QURE

Previous Symbol

CUSIPN/A

CIK1590560

Webwww.uniqure.com

Phone31-20-240-6000

Employees248

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.16

Current Ratio8.62

Quick Ratio8.62

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.28 million

Price / Sales237.45

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.41 per share

Price / Book5.24

Profitability

EPS (Most Recent Fiscal Year)($3.11)

Net Income$-124,200,000.00

Net Margins-2,738.33%

Return on Equity-59.64%

Return on Assets-41.47%

Miscellaneous

Outstanding Shares44,496,000

Market Cap$1.73 billion

Next Earnings Date3/1/2021 (Estimated)

OptionableOptionable

$38.85

-0.41 (-1.04 %)

(As of 01/25/2021 10:55 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

uniQure (NASDAQ:QURE) Frequently Asked Questions

How has uniQure's stock price been impacted by COVID-19 (Coronavirus)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QURE stock has decreased by 17.4% and is now trading at $39.26.
View which stocks have been most impacted by COVID-19.

Is uniQure a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than uniQure?

Wall Street analysts have given uniQure a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but uniQure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for uniQure.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Tuesday, October, 27th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.26 by $2.47. The biotechnology company had revenue of $1.79 million for the quarter, compared to analyst estimates of $96.58 million. uniQure had a negative trailing twelve-month return on equity of 59.64% and a negative net margin of 2,738.33%.
View uniQure's earnings history.

What price target have analysts set for QURE?

13 equities research analysts have issued 12-month price targets for uniQure's stock. Their forecasts range from $52.00 to $85.00. On average, they anticipate uniQure's share price to reach $66.92 in the next year. This suggests a possible upside of 70.5% from the stock's current price.
View analysts' price targets for uniQure or view Wall Street analyst' top-rated stocks.

Who are some of uniQure's key competitors?

Some companies that are related to uniQure include Allakos (ALLK), Schrödinger (SDGR), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), Perrigo (PRGO), Emergent BioSolutions (EBS), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM) and Arena Pharmaceuticals (ARNA).
View all of QURE's competitors.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

Who are uniQure's key executives?

uniQure's management team includes the following people:

Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 49, Pay $908.63k)
Dr. Alexander E. Kuta Ph.D., Exec. VP of Operations (Age 61, Pay $610.61k)
Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Mr. Christian Klemt, Chief Accounting Officer (Age 48)
Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 54)
Ms. Maria E. Cantor, Chief Communications Officer (Age 53)
Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
Mr. James Brady, Chief HR Officer
Mr. Jonathan Garen M.S., Chief Bus. Officer (Age 55)
Mr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 52)

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include OneAscent Financial Services LLC (0.03%) and Pacer Advisors Inc. (0.00%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Jeremy P Springhorn, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Robert Gut and Scott T Mcmillan.
View institutional ownership trends for uniQure.

Which institutional investors are buying uniQure stock?

QURE stock was purchased by a variety of institutional investors in the last quarter, including OneAscent Financial Services LLC, and Pacer Advisors Inc..
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $39.26.

How big of a company is uniQure?

uniQure has a market capitalization of $1.75 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. uniQure employs 248 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here